Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Dow
AstraZeneca
McKesson
Moodys

Last Updated: October 17, 2019

DrugPatentWatch Database Preview

Litigation Details for MERCK & CO, INC. v. SANDOZ INC. (D.N.J. 2010)

See Plans and Pricing

« Back to Dashboard

MERCK & CO, INC. v. SANDOZ INC. (D.N.J. 2010)

Docket   Start Trial Date Filed 2010-05-06
Court District Court, D. New Jersey Date Terminated 2011-06-29
Cause 35:271 Patent Infringement Assigned To Stanley R. Chesler
Jury Demand None Referred To Magistrate Judge Patty Shwartz
Parties MERCK & CO, INC.; MERCK & CO., INC.; MERCK SHARP & DOHME CORP.; SANDOZ INC.
Patents 5,378,804; 5,514,650; 5,952,300
Attorneys CARRIE ANN LONGSTAFF; DAVID E. DELORENZI; ERIC I. ABRAHAM; JASON ALBERT LEONARD; SHEILA F. MCSHANE
Link to Docket External link to docket
Small Molecule Drugs cited in MERCK & CO, INC. v. SANDOZ INC.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for MERCK & CO, INC. v. SANDOZ INC. (D.N.J. 2010)

Date Filed Document No. Description Snippet Link To Document
2010-05-06 1 of U.S. Patent No. 5,378,804 (“the ’804 patent”) and U.S. Patent No. 5,514,650 (“the ’650 patent”) (Patents…Products and cANciDAs®. INFRINGEMENT OF U.S. PATENT NO. 5,378,804 15. Plaintiffs repeat and reallege paragraphs…during the term of the ’804 patent, it would further infringe the ’804 patent under 35 U.S.C. § 271. 18…during the term of the ’650 patent, it would further infringe the ’650 patent under 35 U.S.C. § 271. 23…Defendant. ) ) CIVIL ACTION NO.: COMPLAINT FOR PATENT INFRINGEMENT Case 2:10-cv-02308-SRC -PS Document External link to document
2011-03-03 46 claim terms in U.S. Patent Nos. 5,378,804 (filed Mar. 16, 1993) (the “’804 patent”) and 5,952,300 (filed… It is a bedrock principle of patent law that the claims of a patent define the invention to … in the ’804 patent The parties dispute the meaning of claim 2 of the ’804 patent, which states… in the ’300 patent The parties dispute the meaning of claim 1 of the ’300 patent. This claim …of the ’300 patent, the Court concludes that subphrase “a” in Claim 1 of the ’300 patent should be construed External link to document
2011-03-03 47 the construction of claim terms in U.S.Patent Nos. 5,378,804 and 5,952,300, etc.. Signed by Judge Stanley…2010 29 June 2011 2:10-cv-02308-SRC-PS Patent None District Court, D. New Jersey External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Dow
Boehringer Ingelheim
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.